Oneness Biotech Co., Ltd. AI Stock Analysis
Oneness Biotech Co., Ltd. (4743) AI Stock Analysis
Oneness Biotech Co., Ltd.
(TPEx:4743)
The score is held down primarily by weak financial performance: minimal revenue, persistent losses (about NT$1.04 billion in the latest year) and negative free cash flow that deteriorated year-over-year. The main offset is an exceptionally strong, essentially debt-free balance sheet with more than NT$10 billion of equity, which removes near-term solvency risk and funds the pipeline, alongside three straight years of narrowing losses. Technicals add to the caution, with the price below all major moving averages and a negative MACD, though the oversold Stochastic hints at scope for a near-term bounce. Valuation offers little support, with a P/E above 360x and no dividend. This is a binary, pipeline-dependent story suited only to investors comfortable with development-stage biotech risk.
Oneness Biotech Co., Ltd. (4743) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 22.03B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.35M
- Price to Earnings (P/E)
- -101.4
- Beta (1Y)
- 0.63
- Revenue Growth
- 14.79%
- EPS Growth
- 84.54%
- Country
- TW
- Employees
- 180
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Oneness Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related me...
Oneness Biotech Co., Ltd. Financial Statement Overview
Summary
A classic development-stage biotech profile: a very strong, essentially debt-free balance sheet (debt-to-equity near 0.04, NT$10.3bn equity funding ~88% of assets, Balance Sheet score 71) offset by weak earnings and cash generation. Revenue of roughly NT$129 million is immaterial against R&D spending, producing a net loss of about NT$1.04 billion (Income Statement score 23), while operating and free cash flow were negative NT$449 million and NT$471 million respectively and worsened year-over-year (Cash Flow score 27). Positives include three consecutive years of narrowing losses, renewed revenue growth and a modest burn rate relative to equity; key risks are the ~29% erosion of equity since 2022 and complete dependence on clinical or partnering milestones.
Income Statement
23NegativeBalance Sheet
71PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 149.22M | 129.12M | 117.93M | 86.78M | 1.07B | 65.77M |
| Gross Profit | 57.37M | 35.95M | 63.03M | 32.56M | 844.39M | 45.04M |
| EBITDA | -274.48M | -469.09M | -685.71M | -647.63M | 253.19M | -193.72M |
| Net Income | 59.65M | -1.04B | -1.17B | -1.31B | 359.98M | -412.82M |
Balance Sheet | ||||||
| Total Assets | 11.27B | 11.73B | 13.66B | 15.36B | 15.58B | 15.73B |
| Cash, Cash Equivalents and Short-Term Investments | 5.43B | 5.82B | 7.02B | 7.77B | 8.05B | 7.81B |
| Total Debt | 352.21M | 370.73M | 406.35M | 432.20M | 263.45M | 283.82M |
| Total Liabilities | 872.67M | 1.26B | 859.65M | 866.43M | 700.38M | 1.64B |
| Stockholders Equity | 10.25B | 10.33B | 12.30B | 14.05B | 14.62B | 14.02B |
Cash Flow | ||||||
| Free Cash Flow | -190.51M | -470.89M | -398.86M | -512.23M | -970.19M | -389.19M |
| Operating Cash Flow | -174.55M | -448.93M | -345.58M | -422.18M | -881.00M | -288.89M |
| Investing Cash Flow | -2.34B | 1.07B | 544.16M | -4.82B | 5.74B | 59.54M |
| Financing Cash Flow | -15.52M | -12.49M | 19.70M | 386.58M | 451.87M | 344.67M |
Oneness Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:410579Outperform
TW:472876Outperform
TW:662070Outperform
TW:412348Neutral- TW:474342Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4105 | 79Outperform | TWD 20.44B | 12.21 | ― | 5.47% | 4.54% | -7.38% |
| TW:4728 | 76Outperform | TWD 21.13B | 26.04 | ― | 6.11% | 12.50% | 16.12% |
| TW:6620 | 70Outperform | TWD 20.83B | 72.70 | ― | 1.65% | ― | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4123 | 48Neutral | TWD 22.38B | 23.28 | ― | 6.18% | 3.63% | ― |
| TW:4743 | 42Neutral | TWD 22.59B | -101.39 | ― | ― | 14.79% | 84.54% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4743 | Oneness Biotech Co., Ltd. | 46.25 | -16.55 | -26.35% | |
| TW:4105 | TTY Biopharm Company Limited | 82.10 | 7.54 | 10.12% | |
| TW:4123 | Center Laboratories, Inc. | 28.40 | -5.05 | -15.09% | |
| TW:4728 | SunMax Biotechnology Co. Ltd. | 388.00 | -2.62 | -0.67% | |
| TW:6586 | CHO Pharma, Inc. | 76.20 | 46.05 | 152.74% | |
| TW:6620 | Handa Pharmaceuticals Inc | 136.50 | 16.48 | 13.73% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026